Episode Details
Back to Episodes
Decoding 21 CFR Part 814: A Guide to the FDA's Premarket Approval Pathway
Published 1 year, 2 months ago
Description
This episode provides a detailed overview of the FDA's Premarket Approval (PMA) process, governed by 21 CFR Part 814. We explore the requirements for Class III medical devices, the necessary components of a PMA submission, including non-clinical and clinical data, the FDA's review timeline and procedures, and the post-approval responsibilities of manufacturers.
• What is a Premarket Approval (PMA) and which devices require it?
• How does the FDA define a Class III medical device?
• What are the essential components of a PMA application under 21 CFR Part 814?
• What kind of data is required in the non-clinical and clinical study sections?
• What is the FDA's 180-day review timeline for a PMA?
• What are the possible outcomes of an FDA review?
• What is a PMA supplement and when is it required?
• What are a manufacturer's post-approval responsibilities?
• Can the FDA withdraw a PMA approval after it has been granted?
Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email info@pureglobal.com for tailored support.